Linsitinib

API STANDARDS

Product Details

CAT No.# CS-T-57272
Category API Standards
CAS 867160-71-2
Molecular Weight 421.49
Molecular Formula C26H33N5O
Purity: >98%
Melting Point: >175
Solubility: DMSO
Appearance: Pale Yellow Solid
Synonyms: 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol
Application Notes: Linsitinib is a small-molecule dual insulin-like growth factor-1 receptor (IGF-IR) and insulin receptor (IR) kinase inhibitor. IGF-I receptor (IGF-IR) has been implicated in the promotion of tumorigenesis, metastasis and resistance to cancer therapies and thus Linsitinib may be a useful anticancer agent.
References: Mulvihill, M.M.J. et al.: Fut. Med. Chem., 1, 1153 (2009); Flanigan, S.A. et al.: Clin. Cancer Res., 16, 5436 (2010); McKinley, E.T. et al.: Clin. Cancer Res., 17, 3332 (2011);
COA / MSDS:    View COA    MSDS    Enquire
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
PEOPLE ALSO SEARCHED FOR: 1. (6R,7S)-7-(2-chloroacetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
2. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
3. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
4. Benidipine D7
5. Lauroside D
6. Triazolam 13C D3
7. Icatibant impurity 1
8. BISPHENOL AF (RING-13C12)
9. 0.1% TFA in Water ULC-MS
10. Metamizole EP Impurity C HCl
11. Silodosin Metabolite D4
12. Brivaracetam Carboxylic acid metabolite [UCB 42145]
13. Terbuthylazine D5
14. tibolone (848)
15. (Z)-Dimethylvinphos
16. Silodosin Metabolite
17. 2-Phenoxymethanesulfonanilide
18. Nimesulide EP Impurity A
19. Acetone HPLC
20. Nandrolone Decanoate EP impurity F


SMILES:
O[C@@]1(C)C[C@@H](C2=NC(C3=CC=C4C=CC(C5=CC=CC=C5)=NC4=C3)=C6C(N)=NC=CN62)C1



This page contains information about Linsitinib Cas 867160-71-2 and its API Standards.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."